Access to Follicular Dendritic Cells Is a Pivotal Step in Murine Chronic Lymphocytic Leukemia B-cell Activation and Proliferation

Kristina Heinig¹, Marcel Gärtjen², Michael Grau³, Vanessa Stache¹, Ioannis Anagnostopoulos⁴, Kerstin Gerlach², Raluca A. Niesner⁵, Zoltan Cseresnies⁵,⁶, Anja E. Hauser⁵,⁷, Peter Lenz³, Thomas Hehlgens⁹, Robert Brink⁹, Jörg Westermann¹⁰, Bernd Dörken²,¹⁰, Martin Lipp¹, Georg Lenz¹⁰, Armin Rehm²,¹⁰, and Uta E. Höpken¹
In human chronic lymphocytic leukemia (CLL) pathogenesis, B-cell antigen receptor signaling seems important for leukemia B-cell ontogeny, whereas the microenvironment influences B-cell activation, tumor cell lodging, and provision of antigenic stimuli. Using the murine Epr-Tcl1 CLL model, we demonstrate that CXCR5-controlled access to follicular dendritic cells confers proliferative stimuli to leukemia B cells. Intravital imaging revealed a marginal zone B cell–like leukemia cell trafficking route. Murine and human CLL cells reciprocally stimulated resident mesenchymal stromal cells through lymphotixin-β-receptor activation, resulting in CXCL13 secretion and stromal compartment remodeling. Inhibition of lymphotixin/lymphotixin-β-receptor signaling or of CXCR5 signaling retards leukemia progression. Thus, CXCR5 activity links tumor cell homing, shaping a survival niche, and access to localized proliferation stimuli.

**SIGNIFICANCE:** CLL and other indolent lymphomas are not curable and usually relapse after treatment, a process in which the tumor microenvironment plays a pivotal role. We dissect the consecutive steps of CXCR5-dependent tumor cell lodging and LTβR-dependent stroma–leukemia cell interaction; moreover, we provide therapeutic solutions to interfere with this reciprocal tumor–stroma cross-talk. Cancer Discov; 4(12); 1448–65. © 2014 AACR.

See related commentary by López-Guerra et al., p. 1374.

**INTRODUCTION**

In patients with B-cell chronic lymphocytic leukemia (B-CLL), tumor cell survival and progression are linked to interactions between leukemia cells and nontumor cells in microenvironments of the spleen, peripheral blood, and bone marrow (1–3). Little is known about how CLL cells get access to a putative proliferation and survival niche within lymphoid organs, and a spatial and kinetic resolution of this process is desirable for two reasons. First, the microanatomy of B-cell activation might illuminate the cellular encounters leading to apoptosis resistance versus proliferation induction in CLL cells. Second, signaling events could alter trafficking behavior of leukemia B cells, which is likely relevant for B-cell stimulation.

B-CLL is the most frequent leukemia subtype affecting adults in Western countries (4). It develops as an expansion of clonal mature CD5+ B cells (5, 6), and gene expression profiles of CLL cells show that these malignant B cells resemble antigen-experienced memory B cells (7, 8). The precise cell-of-origin is debated. Depending on differentiation markers, or a putative antigen experience in conjunction with B-cell receptor (BCR) selection, either a marginal zone (MZ) B-2 cell, a B-1 lymphocyte, or a hematopoietic stem cell origin have been proposed (9, 10).

Several genomic aberrations involving karyotypic alterations or mutations in TP53, NOTCH1, and other markers are frequently reported in CLL cases (3, 11). High T-cell leukemia/lymphoma 1 (TCL1) oncogene expression is linked to an aggressive B-CLL phenotype, with leukemic cells displaying a non-mutated immunoglobulin (Ig) receptor and profound ZAP70 expression (3, 12). A mouse B-CLL model has been developed by introducing a transgene encoding human Tc11 under the control of the immunoglobulin heavy chain Eμ-enhancer, resulting in Tcl1 overexpression at the mostly mature stages of B-cell development (13). Tcl1 transgenic mice develop B-CLL–like tumors characterized by an expansion of B220+IgM+CD5+CD11b+ cells, initially localized in the peritoneum and, subsequently, in the spleen, bone marrow, and peripheral blood. This B-CLL model has proven suitable to phenocopy several aspects of the human disease, including low proliferative progression, tissue distribution, and B-cell differentiation status.

As in the migration of their normal cellular counterparts, trafficking and homing of CLL cells to and within the tissue microenvironment are regulated by adhesion molecules in concert with the chemokine–chemokine receptor system (14). The homeostatic chemokine receptor CXCR4 has emerged as a key receptor in the recruitment of and cross-talk between malignant B cells and their protective bone marrow microenvironment (15). Expression of secondary lymphoid organ (SLO)–homing receptors, including CCR7 and CXCR5, on human B-cell non-Hodgkin and Hodgkin lymphoma correlates with their dissemination and tissue localization to and within specific SLO compartments (16, 17).
In B-CLL pathogenesis, a predominant role of BCR signaling in CLL ontogeny has emerged (1). Furthermore, it remains still elusive how the microenvironment assumes a central role in B-cell activation and survival. Here, we aimed to link the mechanisms of leukemia cell activation and the microenvironment dependence during CLL pathogenesis in *Eμ-Tcl1* mice. We intravitally visualized the CXCR5-mediated guidance of leukemic B cells toward splenic B-cell follicles via a route normally taken by MZ B cells. In germinal center (GC) light zones, tumor B cells productively interacted with follicular dendritic cells (FDC), which accelerated proliferation and clinical progression. Leukemia cells initiated LTβR-dependent cross-talk with resident follicular stroma cells, leading to CXCL13 release. Selective targeting of stroma-associated CXCL13 and LTβR signaling abrogated this paracrine feedback loop and retarded leukemogenesis growth.

RESULTS

CXCR5-Dependent *Eμ-Tcl1* Tumor Cell Localization within the Growth-Promoting Environment of the Splenic Follicular Compartment

To assess a putative role of CXCR5-governed leukemia cell migration and expansion in a CLL model, we crossed *Eμ-Tcl1* transgenic and Cxcr5<sup>−/−</sup> mice and followed their spontaneous tumor development compared with *Eμ-Tcl1* mice (Fig. 1A). We detected leukemia B cells (CD19<sup>+</sup>CD5<sup>+</sup>); Supplementary Fig. S1A–S1C and Fig. 1A) in the spleen and peripheral blood of *Eμ-Tcl1* mice after 2 months. In Cxcr5<sup>−/−</sup>*Eμ-Tcl1* mice, disease onset was substantially delayed. At 4 to 6 months of age, tumor cells in *Eμ-Tcl1* mice accounted for 30% to 50% of all lymphocytes, whereas tumor cells were barely detectable in Cxcr5<sup>−/−</sup>*Eμ-Tcl1* mice. After 6 months, *Eμ-Tcl1* mice showed a further increased tumor load (>50%) in spleen and peripheral blood, whereas that in Cxcr5<sup>−/−</sup>*Eμ-Tcl1* mice was still much lower. At 5 to 6 months of age, we also detected more leukemia B cells in the bone marrow of *Eμ-Tcl1* compared with Cxcr5<sup>−/−</sup>*Eμ-Tcl1* mice (Fig. 1A). *Eμ-Tcl1* leukemia cells in the spleen (Fig. 1B) expressed high levels of functional CCR7, CXCR4, and CXCR5 chemokine receptors, as shown in *vitro* by their migration in response to the respective chemokines CCL21, CXCL12, and CXCL13 (Fig. 1C). High expression levels of the homeostatic chemokine receptors were not restricted to the spleen, because lymph node (LN)–, peripheral blood–, and bone marrow–derived leukemia cells also abundantly expressed CCR7, CXCR4, and CXCR5 (Supplementary Fig. S1D). Integrins β1, β2, β7, α4, and αLβ2

---

**Figure 1.** CXCR5 expression accelerates *Eμ-Tcl1* leukemogenesis and is indispensable for tumor cell recruitment to lymphoid B-cell follicles. **A,** tumor load in spleen, lymph node (LN), peripheral blood (PB), and bone marrow (BM) of 7–19– (n = 12–19), 20–27– (n = 10–12), 28–39– (n = 9–42), and 40–48– (n = 12–52) week-old *Eμ-Tcl1* and 7–19– (n = 9–15), 20–27– (n = 8–17), 28–39– (n = 36–52), and 40–48– (n = 16–20) week-old Cxcr5<sup>−/−</sup>*Eμ-Tcl1* mice. CD19<sup>+</sup>B220<sup>+</sup>CD5<sup>+</sup> tumor cells are presented as percentages of all lymphocytes with means. Error bars indicate Min to Max. P values were determined by the unpaired Student’s t test. **B,** chemokine receptor expression on splenic CD19<sup>+</sup>B220<sup>+</sup>CD5<sup>+</sup> gated tumor cells of diseased *Eμ-Tcl1* and Cxcr5<sup>−/−</sup>*Eμ-Tcl1* mice (n = 4–7 mice/mark; isotype control; shaded curve). **C,** chemotaxis of *Eμ-Tcl1* (left) or Cxcr5<sup>−/−</sup>*Eμ-Tcl1* (right) cells toward CCL21 (100 nmol/L), CXCL12 (25 nmol/L), and CXCL13 (300 nmol/L). Error bars indicate mean ± SEM of three independent experiments with triplicates for each chemokine. P values were determined by the Mann-Whitney test. (continued on following page)
CXCR5 and Lymphotoxin-Dependent Leukemia Growth

expression for LT
quantitative real-time PCR (qRT-PCR) revealed substantial
tumor cells, B cells, and MOMA-1
absent from B-cell follicles and were mostly found in the MZ
E
WT congenic recipients . After 72 hours, leukemia cells were

Three days after i.v. transfer, spleen sections were stained for CD45.2
Tcl1
cells (Supplementary Fig. S2A and S2B). Hence,

(LFA-1) were readily detected on all
Eμ-Tcl1 leukemia cells and, quantitative real-time PCR (qRT-PCR) revealed substantial
expression for LTα, LTβ, and TNFα in Eμ-Tcl1 and Cxcr5−/− Eμ-Tcl1 cells (Supplementary Fig. S2A and S2B). Hence, Eμ-Tcl1
leukemia B cells are equipped with functional homoeostatic
chemokine receptors and integrins that enable them for
access to SLOs.

We confirmed abundant high CXCR5 expression on
human CLL tissue (Supplementary Fig. S2C) and on human
peripheral CLL blood samples (Supplementary Fig. S2D).
Much weaker expression was observed on CLL cells localized
within proliferation centers, which are thought to harbor a
proliferative fraction of CLL leukemia B cells (18).

Next, malignant B cells derived from diseased Eμ-Tcl1 or
Cxcr5−/− Eμ-Tcl1 mice were adoptively transferred into wild-type
(WT) congenic recipients. After 72 hours, leukemia cells were
detected in the spleen, peripheral blood, and bone marrow.
Eμ-Tcl1 cells were predominantly localized within splenic B-cell
follicles (Fig. 1D). In contrast, Cxcr5−/− Eμ-Tcl1 cells were completely
absent from B-cell follicles and were mostly found in the MZ
outside the metallophilic macrophage ring (MOMA-1+). To
further assess whether this follicular localization had any
consequences on leukemia progression, we applied a CXCL13
antibody to inhibit CXCR5 signaling. Expansion of adoptively
transferred tumor B cells was substantially diminished in
spleens of CXCL13-treated mice (Fig. 1E).

Collectively, these data indicate that CXCR5 contributes to
accelerated leukemia development, potentially by conferring a
survival advantage to Eμ-Tcl1 tumor cells within the B-cell
follicle.

Gene Expression Signatures Indicate a Proliferative
Advantage in Cxcr5-Expressing Eμ-Tcl1 Leukemia
Compared with Cxcr5−/− Eμ-Tcl1 Leukemia

The slower kinetics of tumor growth in Cxcr5−/− Eμ-Tcl1 transgenic mice could relate to a reduced proliferation rate. Using
genome-wide expression arrays, we examined relative changes in
gene expression of splenic leukemia cells derived from diseased
Eμ-Tcl1 versus Cxcr5−/− Eμ-Tcl1 mice. Gene set enrichment analysis
(GSEA) identified seven different proliferation signatures that
discriminated Cxcr5+/− from Cxcr5−/− leukemias (Fig. 2A and B;
Supplementary Fig. S3A). For example, the gene-expression signa-
ture of the neighborhood of the cell division cycle 2 (CDC2; G1–S
and G2–M) in the GNF2 expression compendium (19) predicted
a proliferative advantage in CXCR5-expressing Eμ-Tcl1 tumor
cells and included genes involved in cell-cycle regulation, DNA

![Image](100x459 to 385x674)

**Figure 1.** (Continued) D, adoptive transfer of 2 × 10^7 splenic leukemia cells of Eμ-Tcl1 and Cxcr5−/− Eμ-Tcl1 mice (CD45.2+) into CD45.1+ B6 recipients. Three days after i.v. transfer, spleen sections were stained for CD45.2+ tumor cells, CD3− T cells, and IgD+B cells (n = 8–9/group; top). Bottom, detection of tumor cells, B cells, and MOMA-1+ metallophilic macrophages (n = 8–9/group). Scale bars, 100 μm. E, in vivo blockage of the CXCL13 signaling pathway by treatment of tumor challenged mice (1 × 10^7 Eμ-Tcl1 cells i.v. on day 1) with 50 μg anti-CXCL13 or isotype Ab intraperitoneally (i.p.) at the days indicated (n = 3/group). Tumor cell (CD19+ B220− IgD+) load was assessed by flow cytometry at day 24. Error bars indicate mean ± SEM. P values were determined by the unpaired Student t test. *, P ≤ 0.05; **, P ≤ 0.01; ***, P ≤ 0.001. n.s., not significant.
Gene Set Enrichment Analysis for neighborhood of CDC2 cell division cycle 2

(P1 to S and G2 to M; from the GNF2 expression compendium via the Molecular Signatures DB v3.0; translated from Homo sapiens to Mus musculus via gene homology; measured: genes = 56; enrichment score = 0.844; P_SEA = 0.0011 via 870 permutations; FDR = 0.001)

Gene set enrichment analysis for comparison of Cxcr5+/+ vs Cxcr5−/−

(mean: signed [p] values; based on the two sample t test)
synthesis, and protein translation. Conversely, CXCR5 +/− versus CXCR5 −/− leukemia did not differentially express gene sets of apoptosis-mediating pathways like the Kyoto Encyclopedia of Genes and Genomes (KEGG) apoptosis signature (Fig. 2C, ref. 20).

Eμ-Tc1l leukemia B cells represent the unmutated and aggressive type of B-CLL (21). A bias toward the restricted use of Vμ genes was noted, indicating that the expanded CDS B-cell population in Eμ-Tc1l mice could be derived from B-1 lineage cells. We performed a transcriptome analysis of leukemia cells, murine B-1 cells, and MZ B cells (Fig. 2D and E). Two gene expression signatures comprised of the top 100 downregulated and upregulated genes in B-1 cells compared with MZ B cells were defined. When gene expression of these signatures was compared in leukemia cells and in follicle cells derived from WT mice, a strikingly higher similarity of Eμ-Tc1l leukemia cells to B-1 B cells as compared with MZ B cells was revealed.

Likewise, Eμ-Tc1l and CXCR5-deficient mice showed differences in pathogenic events at the onset of the disease (22). Leukemia cells were retrieved and we used qRT-PCR to assess their gene expression pattern, focusing on genes reportedly involved in CLL survival (23). WNT6 and WNT10A were modestly elevated in Eμ-Tc1l tumor cells, whereas CcR5 +/− Eμ-Tc1l leukemia cells showed substantially higher gene expression for the transcription factor RUNX2 (Supplementary Fig. S3B). The cell-cycle inhibitor p21, a transcriptional target of RUNX2 (24), was also upregulated in CcR5 +/− Eμ-Tc1l leukemia (Supplementary Fig. S3C), indicating that CXCR5 confers Eμ-Tc1l tumor cells with a proliferative advantage.

When leukemia cells were cocultured with the FDC/HK cell line, the activities of serine/threonine kinases p42/p44, p38, and AKT were indiscriminable in both genotypes (Supplementary Fig. S3D). In addition, a comparable proliferation rate of WT and CXCR5-deficient tumor cells was detectable when leukemia cells were cocultured with the stroma cell line MZ-10B4 (Fig. 2F). This indicates that when tumor cells get access to stromal cell support in vitro, their proliferation is supported. In vivo, CXCR5 controls this access to a tumor growth-promoting stromal niche.

**Eμ-Tc1l Leukemia Cells Move Directly across the MZ–WP Border to Gain Access to the B-cell Follicle**

Lymphocyte transition from the blood into the spleen occurs at the MZ. Follicular B and T cells then migrate along the fibroblastic reticular cell (FRC)–rich MZ bridging channels (MZBC) toward the splenic white pulp (WP) and eventually enter the periarteriolar lymphoid sheaths (PALS). This movement is largely CCR7-dependent (25). In contrast, MZ B cells undergo CXCR5- and S1P1-controlled constitutive shutting between the MZ and the follicle (26).

It is unknown how CLL cells access the B-cell follicle. Applying a sequential static imaging approach, SNARF-1–labeled tumor or B cells were adoptively transferred into B6 recipients. One to five hours later, spleens were stained with anti-B220 to locate B-cell follicles and anti–MOMA-1 to highlight the border between WP and MZ (Fig. 3A and B). We counted the numbers of labeled Eμ-Tc1l leukemia cells or normal B cells in four regions of the spleen: the red pulp (RP; MOMA-1 B220 − ), MZ (MOMA-1 B220 +), B-cell follicle (MOMA-1 B220 −), and T/B zone interface (Fig. 3A and B).

One hour after transfer, normal B cells were found predominately in the RP but also in the MZ (Fig. 3B and C), whereas >50% of tumor cells were localized either within the MZ or in B-cell follicles (Fig. 3A and C). Two hours after transfer, B cells were still predominantly located in the RP, with a smaller proportion in the MZ, and single B cells appeared at the T/B-cell border. Tumor cells were equally distributed between MZ and B-cell follicle with a smaller proportion in the RP. To three hours after transfer, the proportion of leukemia cells in B-cell follicles further increased, whereas tumor cells remained absent from the T/B-cell border (Fig. 3A–D).

In contrast, B lymphocytes transiently accumulated at the T/B zone border (between 2 and 3 hours) before entering the B-cell follicle (3–5 hours; Fig. 3B–D).

The positioning of B cells at the T/B-cell border is regulated by CCR7 and EBI2 chemotactic activity (27). After adoptive transfer, both Ccr7 +/− and Ccr7 −/− leukemia cells showed the same direct migratory route from the MZ into B-cell follicles, with an accumulation at the FDCs (Supplementary Fig. S4A). Likewise, Ebi2 +/− Eμ-Tc1l cells exhibited the same localization behavior (Supplementary Fig. S4B and S4C). Clinically, spontaneous leukemia development in Ebi2 +/− Eμ-Tc1l double-transgenic animals compared with Eμ-Tc1l mice revealed no alteration in tumor growth (Supplementary Fig. S4D).

In summary, Eμ-Tc1l leukemia B cells directly cross the MZ sinus, reaching the B-cell follicle faster than follicular B cells, and this process is tightly regulated by the CXCL13–CXCR5 signaling axis.
**Figure 3.** *Eμ-Tcl1* tumor cells exhibit different migratory routes and temporal migration pattern to and within lymphoid follicles compared with B lymphocytes. A and B, 2 × 10^7 SNARF-1-labeled (red) splenic *Eμ-Tcl1* leukemia cells or follicular B cells were transferred i.v. into B6 mice. Spleen sections were stained for MOMA-1+ metallophilic macrophages and B220+ B cells to distinguish the MZ (MOMA-1+ B220+; MZ), the B-cell follicle (MOMA-1 B220; Fo), RP, and T cell zone (MOMA-1 B220; T), and one representative section is shown for each time point. Scale bar, 100 μm. C, quantification of WT B cells and *Eμ-Tcl1* leukemia cell localization within the zones as indicated in A and B. D, the percentage of B cells or *Eμ-Tcl1* leukemia cells located at the B/T cell border or in the MOMA − B220+ B-cell zone is presented as a time curve. Bars represent mean ± SEM of two independent experiments with n = 2–5 mice for each group and time point. P values were determined by the unpaired Student t test. *, P ≤ 0.05; **, P ≤ 0.01; n.s., not significant.

---

**Eμ-Tcl1** Leukemia Cells Tightly Colocalize with the Follicular FDC Network and Exhibit Strong ZAP-70/Syk and BTK Activity

FDCs reside within primary follicles and in the GC light zone of secondary B-cell follicles. They express CXCL13, which enables CXCR5-expressing B cells to migrate into lymphoid follicles. Because a strong correlation has been proposed between antigen-stimulated BCR signaling and the clinical course of CLL, we identified follicular stromal networks that locally interact with *Eμ-Tcl1* leukemia cells. Eight hours after transferring leukemia cells, tumor cells tightly intermingled with FDCs (Fig. 4A). These cells stained strongly for the proliferation marker Ki67 (CD45.2+Ki67+), indicating a proliferation-driving interaction. Of all Ki67+ leukemia cells, 77.5% ± 5.8% cells were tightly associated with the FDC networks, whereas only 22.1% ± 3.6% of follicular Ki67+ leukemia cells were located outside of the FDC networks (Fig. 4B).

Next, we simultaneously injected differentially labeled follicular B cells (B220+CD21intCD23hi) with *Eμ-Tcl1* leukemia cells and quantified the proportion of transferred cells within the FDC-rich zone (Fig. 4C). Less than 50% of all transferred follicular B cells were found at the FDC networks. In contrast,
CXCR5 and Lymphotxin-Dependent Leukemia Growth

Figure 4. Functional interaction of Eμ-Tcl1 tumor cells with FDC networks. A, splenic Eμ-Tcl1 leukemia cells were sorted and 2 × 10^7 SNARF-1-labeled cells (red) were transferred i.v. into recipient mice (n = 3). Eight hours later, spleen sections were stained for CD21–CD35+ FDCs and B220+ B cells. A zoomed inlet (boxed area; left) is additionally shown. Scale bar, 100 μm. B, 2 × 10^7 Eμ-Tcl1 leukemia cells were transferred i.v. into congenic recipient mice. Three days later, spleen sections were stained for tumor cells (CD45.2+, FDC-M2+ FDCs, and the proliferation marker Ki67 [6–9 sections/mouse; n = 3]. C, splenic follicular B cells (B220+CD21–CD23+) and Eμ-Tcl1 lymphoma cells were sorted and labeled with CMAC (FoB, in blue) and SNARF-1 (leukemia cells, in red), respectively. Cells [1 × 10^7] of both groups were cotransferred into recipient mice (n = 3) and localization was analyzed after 8 hours. A representative section and an enlarged inlet of the boxed area are shown. Scale bar, 50 μm. D, quantification of the proportion of transferred leukemia cells compared with follicular B cells localized within the FDC rich zone of the B-cell follicle, as marked by the dashed white line in C. Error bars indicate mean ± SE of three independent experiments with a total of nine to 13 analyzed sections. E, immunoblot analysis of phosphorylated and total BTK from leukemia cells (n = 14 mice; #1 and #2 indicate two representative leukemia samples), and follicular B cells (n = 4 mice, one representative sample depicted) as a control. Membranes were incubated with anti–phospho-ZAP-70 Tyr319/Syk Tyr352 (top), and anti-GAPDH (bottom). Bar diagram depicts the quantification of the ratios. Error bars indicate mean ± SE. **p < 0.01. F, immunoblot analysis of phosphorylated and total BTK from leukemia cells (n = 3 mice; #1–3 indicate three leukemia samples), and follicular B cells (n = 3 mice; #1–3, three samples) as a control. Membranes were incubated with anti–p-BTK (top), and total BTK (bottom). Bar diagram depicts the quantification of the ratios. Error bars indicate mean ± SEM. G, Eμ-Tcl1 mice with a tumor burden of 21% to 25% (n = 10) in peripheral blood were injected i.p. with 1 mg BrdUrd for 3 days. Peripheral blood (PBL), spleen, and peritoneal cavity (PerC)-derived Eμ-Tcl1 leukemia cells were analyzed for BrdUrd uptake. (continued on next page)

more than 70% of leukemia cells strongly colocalized with FDCs (Fig. 4D).

Consistent with the animal model, FDCs could be detected in human CLL specimens at variable rates and shapes, ranging from distinct reticular forms to more complex networks (Supplementary Fig. S5).

Leukemic cells of patients with progressive CLL express the protein tyrosine kinase ZAP-70, which is functionally associated with increased BCR signaling (28). Another tyrosine kinase that is uniformly overexpressed and constitutively active in CLL is Bruton’s tyrosine kinase (BTK; refs. 29–31). Here, using an antibody that cross-reacts with phosphorylated (p) ZAP-70 and p-Syk (32), we showed substantially enhanced expression of p–ZAP-70/Syk in Eμ-Tcl1 leukemia cells compared with B lymphocytes. This finding was corroborated with a p-BTK antibody (Fig. 4E and F), indicating that Eμ-Tcl1 leukemia cells exhibit increased BCR activity.

BCR engagement and growth factor supply could depend on the environmental context. Here, tissue-resident leukemia cells from the spleen showed an enhanced proportion of cells in S-phase (BrdUrd4%), suggesting a stronger stimulus in SLOs compared with cells derived from peripheral blood (Fig. 4G). Thus, Eμ-Tcl1 leukemia cell contacts to FDC networks could be a prerequisite for tumor cell proliferation that is enhanced by BCR signaling and local cytokine provision.
To further dissect these mechanisms, we cocultured seven different Ep-Tcl1 leukemia cell clones in the presence of FDC/HK cells (33). When HK cells were prestimulated with LTα1β2, an almost 2-fold higher survival rate of leukemia cells as compared with HK cells alone was seen. This indicated that engagement of the LTβR could induce provision of B-cell growth factors (Fig. 4H). Next, we mimicked cytokine and growth factor conditions that were suggested to support either GC B-cell proliferation or follicular B-cell lymphoma expansion (34, 35). When supplemented, a substantial increase in cell proliferation was obtained for BAFF, CXCL12, Sonic hedgehog (SHH), hepatocyte growth factor (HGF), CXCL13, and IL15 (Fig. 4H). The use of the γ-secretase inhibitor DAPT, and thus NOTCH pathway blockade, served as a negative control. To discriminate between an antiapoptotic effect and a proliferation induction, we repeated this assay for selected cytokines and measured instead BrdUrd uptake.

We observed enhanced proliferation rates of Ep-Tcl1 leukemia cells (BrdUrd*) after stimulation with LTα1β2 and an even stronger proliferation in the presence of IL15 (Fig. 4I). Treatment of cocultures with the CXCR4 antagonist AMD3100 inhibited BrdUrd uptake (Fig. 4I), which supports the notion that the CXCR4 signaling directly stimulates proliferation of CLL cells. Inclusion of the Gai/o-protein inhibitor pertussis toxin (PTX) considerably diminished leukemia B-cell viability in HK cocultures (Supplementary Fig. S6A). Hence, BrdUrd uptake could not be reliably determined because of the predominant fraction of apoptotic leukemia cells.

In accordance, when human CLL cells were cocultured with FDC/HK cells, enhanced proliferation of CLL cells was also observed and could be further enhanced by adding IL15 (Supplementary Fig. S6B). Pretreatment with LTα1β2 had a modest effect, which might be explained by higher endogenous expression of LTβR and LTβR in human CLL cells (Fig. 7E).
CXCRI5 and Lymphotoxin-Dependent Leukemia Growth

If antigen recognition is important for Eµ-Tcl1 leukemia cell growth, then restricting the antigen specificity of leukemia cells against an irrelevant antigen might reduce their fitness in vivo. We generated Eµ-Tcl1 x BCRHEL double-transgenic mice and analyzed them after repetitive immunization with the cognate antigen HEL or without (Supplementary Tables S1 and S2) for the development of a clonal B-CLL-like disease. Leukemia cell development equipped with the cognate BCRHEL could not be observed in nonimmunized or HEL-immunized mice, indicating that sole stimulation of the BCRHEL does not confer sufficient signaling to promote Eµ-Tcl1 leukemia development.

The Dynamics of Eµ-Tcl1 Leukemia Cell Localization in the CD21⁺CD35⁺ GC Light Zone

The localization of Eµ-Tcl1 tumor cells near FDCs suggested that this network might provide the combined chemotactic, nutritive, and antigenic stimuli for BCR engagement. To visualize the dynamic behavior of Eµ-Tcl1 leukemia cells in relation to FDCs, we injected Alexa Fluor 568-conjugated anti-CD21/CD35 Fab fragments for intravital FDC staining (Supplementary Fig. S7), together with CFDA-labeled Eµ-Tcl1 leukemia or B cells. During a 30-minute imaging period, we tracked individual motile Eµ-Tcl1 leukemia cells or B cells that were localized within the B-cell follicle or close to the FDCs for as long as the cells remained within the z stacks (height, 40–50 μm) of optical sections (Supplementary Movies S1 and S2). Tracks of motile leukemia or B cells were also projected onto an image of the entire z stack, representing a midpoint in the imaging time period (Fig. 4f). We could distinguish between a more stationary FDC-associated and a more motile follicular-located leukemia cell population based on total displacement from their origin (Fig. 4k), track velocity (Fig. 4l), and total track length (Fig. 4m).

All three parameters were substantially decreased when leukemia cells were close to the FDC networks, as opposed to those located within the outer B-cell follicle (Fig. 4k–m; Fig. 4f, top; Supplementary Movie S1). This association was also observed in follicular B-cells (Fig. 4k–m and Supplementary Movie S2), but fewer B cells were associated with FDCs (Fig. 4d and j, bottom). We conclude that the decreased displacement rate and increased interaction time of leukemia B cells with FDCs could result from the tumor cells’ cognate nature and their ability to encounter antigen-laden FDCs.

To assess follicular Eµ-Tcl1 leukemia positioning following the organization of GCs into dark and light zones, we immunized B6 mice with sheep red blood cells. GC B-cell positioning in the dark zone is crucially dependent on high CXCR4 expression (36). SNARF-1–labeled tumor cells were i.v. transferred; 8 hours later, splenic sections were stained for PNA⁺ GCs (centroblasts, dark zone), CD21⁺CD35⁺ FDC networks (light zone), and IgD⁺ B-cell follicles (Fig. 5a). Tumor cells were also pretreated with the CXCR4 antagonist AMD3100 (Fig. 5b–d). Eµ-Tcl1 leukemia cells localized exclusively in the CD21⁺CD35⁺ GC light zone, independently of CXCR4-signaling inhibition (Fig. 5b). Inhibition of CXCR4 signaling after AMD3100 treatment was confirmed in vitro in a chemotaxis assay (Fig. 5d).

The sphingosine-1-phosphate receptor S1PR2 helps to confine B cells to the GC (37). GC B cells showed the highest gene expression of S1pr2. In contrast, Eµ-Tcl1 leukemia cells exhibited low S1pr2 expression comparable to the amounts of S1pr2 in MZ B cells (Fig. 5e). Collectively, Eµ-Tcl1 leukemia cells are predominantly recruited to the CD21⁺CD35⁺ GC light zone, but they do not access the PNA⁻ dark zone.

In Irradiated Mice Eµ-Tcl1 Leukemia Cells Exhibit Enhanced Proliferation in Close Proximity to FDCs

Clinically, an unresolved problem in the treatment of indolent lymphoma is its propensity to relapse and to progressively develop chemo resistance. The close association of Eµ-Tcl1 leukemia cells with FDCs raised the question of whether tumor cells might reciprocally support or initiate stromal cell network differentiation. To analyze the mechanisms of a putatively stroma-regulated treatment failure, we first assessed the stroma-inducing capacity of tumor cells in Rag2⁻/⁻ mice that are devoid of mature lymphocytes and lack FRCs and FDCs. These mice still have MAdCAM-1⁺ marginal reticular cells (MRC), which produce CXCL13 and express the LTβR. Over a 21-day observation period, Eµ-Tcl1 leukemia cells induced formation of follicular-like CXCL13-expressing FDC (CD21⁺CD35⁺) networks in Rag2⁻/⁻ mice (Supplementary Fig. S8a). Leukemia-loaded spleen also upregulated CXCL13 und LTβ gene expression (Supplementary Fig. S8b).

Radiotherapy eliminates hematopoietic cells, whereas mesenchymal stromal elements survive. To assess whether residual leukemia cells could exploit stromal contacts and engage with FDCs and MRCs, we transferred Eµ-Tcl1 cells into irradiated congenic recipients. Although essentially all benign B220⁺ B cells were depleted after 48 hours, FDCs persisted and the MRC ring expanded (Fig. 6a, top left). Transferred CLL cells accumulated around the FDC networks in an even stronger manner than in untreated mice (Fig. 6a, bottom). Functionally, transfer into irradiated hosts conferred tumor cells with an enhanced proliferative capacity (Fig. 6b and c), and the rate of tumor cells in close proximity to FDC networks that stained strongly for Ki67⁺ was substantially higher compared with untreated controls (Fig. 6b). Irradiation of mice substantially enhanced splenic BAFF gene expression about 4-fold, whereas APRIL was weaker upregulated (Fig. 6d). We confirmed expression of the corresponding cytokine receptor BAFFR on leukemia cells (Fig. 6e).

To demonstrate that irradiation enhances proliferation in a BAFF-dependent manner, we transferred tumor cells together with a blocking anti-BAFF antibody into irradiated mice. Treatment with the anti-BAFF antibody completely abrogated irradiation-induced proliferation in Eµ-Tcl1 tumor cells (Fig. 6f).

Taken together, CLL cells are recruited to mesenchymal stromal cells, which in turn promote chemokine-mediated tumor cell attraction, growth acceleration through BCR stimulation, and paracrine provision of cytokines.

Stromal LTβR Signaling Is Crucial for Maintaining FDC Structures and Accelerates Eµ-Tcl1 Leukemia Progression

FDC stimulation with cell-bound LTβR or soluble LTα/ TNFR1 agonist can induce the expression of CXCL13 and other cytokines (38). Because the leukemia cell itself was also a source of lymphotixin (Supplementary Fig. S2b), we
**Figure 5.** Eμ-Tcl1 tumor cells localize in the GC-associated FDC-rich light zone independently of Cxcr4 and S1pr2 signaling. **A,** WT mice were immunized with sheep red blood cells (SRBC). At day 7, 2 × 10^7 SNARF-1–labeled sorted splenic Eμ-Tcl1 tumor cells were transferred i.v. into recipients. Eight hours later, localization of tumor cells (red) was detected in splenic sections by staining for GC-associated FDC-rich light zone (CD21^+CD35^+) and PNA^+ dark zone (left) or by staining of IgD^+ B-cell follicular areas and PNA^+ dark zone (right). Two consecutive slides were stained. Scale bar, 50 μm. **B,** B6 mice were immunized as in A. At day 8, 2 × 10^7 sorted splenic Eμ-Tcl1 leukemia cells were pretreated without AMD3100 (two independent experiments) or with AMD3100 (three independent experiments), followed by i.v. transfer into recipient mice. Eight hours later, localization of tumor cells (red) was detected in splenic sections by staining for GC-associated FDC-rich light zone (CD21^+CD35^+) and PNA^+ dark zone (top) and for CD21^+CD35^+ FDCs and B220^+ B cells (bottom). **C,** quantification of the proportion of leukemia cells within the light zone (green) or within the PNA^+ dark zone (blue). Bars represent mean ± SEM of three to five independent experiments. **D,** chemotaxis of Eμ-Tcl1 tumor cells toward CXCL12 with and without treatment with AMD3100. Bars represent mean ± SEM of two to four independent experiments with triplicates per each group. *P ≤ 0.05, ***, *P ≤ 0.001. **E,** qRT-PCR of S1pr2 in sorted tumor cells of Eμ-Tcl1 (n = 4) mice, and in follicular B (B220^+CD21^hiCD23^lo; Fo B), MZ B (B220^+CD21^loCD23^hi; MZ B), and GC B (B220^+GL7^hiFas^+; GC B) cells (one experiment with 3 mice/group). Transcript expression was normalized to Gapdh. Error bars indicate mean ± SEM.
Figure 6. \( \text{E}_{\mu}-\text{Tcl1} \) tumor cells localize at radio-resistant FDC networks and exhibit stronger proliferation in the spleens of irradiated mice. \( \text{A} \), spleens of lethally irradiated (9.25 Gy) or untreated B6 CD45.1 mice were harvested 48 hours \((n=2/\text{group})\) after treatment and stained for B220\(^+\) cells, MAdCAM-1\(^+\) MRCs, and FDC-M2\(^+\)stromal cell networks. Representative sections are shown (top). SNARF-1-labeled \( \text{E}_{\mu}-\text{Tcl1} \) cells \((2\times10^7; \text{CD45.2})\) were adoptively transferred into lethally irradiated recipients \((n=3)\) or into nonirradiated controls \((n=2)\). Forty-eight hours after tumor challenge, spleen sections were stained with CD45.2\(^+\) and FDC-M2\(^+\) (blue; bottom) or \( \text{B} \), CD45.2\(^+\), FDC-M2\(^+\), and Ki67\(^+\) antibodies. Representative sections are shown. Scale bars, 100 \( \mu \text{m} \). \( \text{C} \), eFluor670-labeled \( \text{E}_{\mu}-\text{Tcl1} \) leukemia cells \((2–5\times10^6)\) were adoptively transferred into irradiated mice \((n=3)\) or into untreated recipients \((n=2)\). Forty-eight hours later, proliferation of splenic tumor cells was evaluated according to eFluor670 dilution; a representative histogram shows staining of tumor cells recovered from untreated or irradiated mice. \( \text{D} \), splenic Baff and April mRNA transcripts of irradiated or nonirradiated mice with or without tumor cell challenge \((n=2–3 \text{ mice/\text{group}})\). Transcript expression was normalized to Gapdh. Error bars indicate mean ± SEM. \( \text{E} \), surface expression of BAFFR on splenic \( \text{E}_{\mu}-\text{Tcl1} \) leukemia cells \((\text{CD19}^+\text{CD5}^+\); \( n=5 \) transgenic \( \text{E}_{\mu}-\text{Tcl1} \) mice) was confirmed by flow cytometry (isotype Ig control, shaded curve; anti-BAFFR Ig, solid line). \( \text{F} \), blockage of the BAFF signaling pathway by injecting 50 \( \mu \text{g} \) anti-BAFF or isotype Ab together with 5–10\( \times10^6 \) eFluor670-labeled \( \text{E}_{\mu}-\text{Tcl1} \) leukemia cells i.v. \((n=3–4/\text{group})\). Forty-eight hours later, proliferation of splenic tumor cells was evaluated according to eFluor670 dilution; a representative histogram shows staining of tumor cells recovered from isotype or anti–BAFF-treated irradiated mice compared with cells from nonirradiated mice (set arbitrarily to 100%; \( n=3 \) independent experiments) are depicted as bars ± SEM (right). Means and significance calculated by the unpaired Student’s t test are shown. *, \( P \leq 0.05; **, P \leq 0.01. \)
hypothesized that leukemia cell–associated LTβ conferred the ligand for LTβR activation on FDCs and MRCs. To assess this regulatory feedback loop, we inhibited LTβR signaling in Eμ-Tcl1 mice using an LTβR–Ig fusion protein. Spontaneously diseased Eμ-Tcl1 mice with a 5% to 15% tumor load in peripheral blood were treated with the decoy receptor protein LTβR–Ig. Eμ-Tcl1 mice treated with a control Ig showed a substantially increased tumor load in peripheral blood from days 0 to 38 of treatment, whereas no such increment was observed in LTβR–Ig–treated mice (Fig. 7A). Tumor load in the spleen of isotype-treated Eμ-Tcl1 mice was also higher than in LTβR–Ig–treated animals (Fig. 7B). Immunohistology showed substantial FDC disappearance (Fig. 7C) and a severe disturbance of MAdCAM-1+ and BP-3+ B-cell follicle stromal structures (Supplementary Fig. S9A) in LTβR–Ig–treated animals. Splenic Cd21 and Cxcl13 gene expressions were lower in LTβR–Ig–treated Eμ-Tcl1 mice compared with controls (Fig. 7D).

Supporting a pathogenic role of LTβR signaling, disease onset and progression were substantially delayed in Lta−/− Eμ-Tcl1 double-transgenic mice compared with Eμ-Tcl1 animals (Supplementary Fig. S9B). Hence, tumor cell production of LTα accelerates tumor growth. Conversely, interference with LTβR signaling leads to growth reduction in a murine CLL model.

In line with the data from Eμ-Tcl1 mice, lymphoxygenin and TNFα transcripts could be detected in sorted human CLL cells, normal B cells, and in the human B-CLL line MEC-1 (Fig. 7E). Adoptive transfer of MEC-1 cells into NOD/SCID/c−/− mice elicited a follicular-like FDC network (Fig. 7F, left), a process which could be completely abrogated by LTβR–Ig treatment (Fig. 7F, right). Thus, LTβR signaling is an essential part of the reciprocal relationship between leukemia B cells and mesenchymal stromal cells.

**DISCUSSION**

In this study, we tracked the trafficking routes of murine CLL cells into protective microenvironmental niches in SLOs, and identified FDCs as a crucial resident stromal cell population that supports consecutive steps of leukemia pathogenesis. Using the Eμ-Tcl1 transgenic mouse (13) as a CLL model, we also obtained functional evidence that the chemokine...
CXCR5 and Lymphotoxin-Dependent Leukemia Growth

Research Article

The receptor CXCR5 has a dominant role in leukemia cell microanatomic localization. 

*Eμ*Tcl1* B cells showed a hierarchy among expressed homeostatic chemokine receptors. CXCR4 has been identified as a survival factor in CLL (39) and as an important homing receptor of neoplastic B cells to the bone marrow (40), whereas CXCR5 expression is predominantly associated with CLL positioning in SLOs (41). Although CXCL12-CXCR4 engagement accelerates human B-CLL and murine *Eμ*Tcl1 leukemia cell proliferation in vitro, in vivo this activity requires access to a CXCL12-providing niche. In our murine CLL model, CXCR5 crucially controls homing of leukemia cells into the B-cell follicles of SLOs. CXCR4 could not compensate for CXCR5 deficiency regarding their migratory functions: CXCR5-deficient leukemia cells were restricted to the MZ zone but not attracted to the B-cell follicle, and tumor cells remained absent from the dark zone of the GC, the attraction to which is CXCL12-CXCR4 governed (36).

In the absence of CXCR5, spontaneous onset of disease in *Eμ*Tcl1 mice was severely delayed. Gene expression profiling uncovered a proliferative advantage in CXCR5-expressing *Eμ*Tcl1 tumor cells, whereas no obvious differences were found in apoptosis-mediating pathways. In conjunction with a compartment-specific higher proliferation rate, this observation is in line with the view that B-CLL is not a static or accumulative disease that simply results from long-lived lymphocytes defective in apoptosis (42, 43).

Migration of normal B cells toward follicles is mediated by the CXCL13–CXCR5 signaling axis and a stromal cell network (25, 44). CXCL13, which is produced by the FDC network and MRCs, guides circulating naïve B cells in the proximity of FDCs, a prerequisite for the formation of B-cell follicles (36). Moreover, CXCR5 also plays a unique role in trafficking and homing of B-1 B cells (45). In patients with CLL, leukemia cells express high levels of functional CXCR5, and significantly higher CXCL13 serum levels were found compared with healthy controls (41).

With regard to these correlative studies in patients with CLL, we aimed to dissect the CXCR5-dependent spatial positioning of *Eμ*Tcl1 leukemia cells in vivo. We found that upon

Figure 7. (Continued) D, splenic *Ccl19, Ccl21, Cxcl12*, and *Cxcl13* mRNA expression of *Eμ*Tcl1 mice treated with either LTR-Ig (*n* = 9) or control Ig (*n* = 9) were analyzed by qRT-PCR. Gene expression was calculated relative to *Gapdh*. Error bars indicate mean ± SEM. *P* values were determined by the Mann-Whitney test. *, *P* ≤ 0.05; **, *P* ≤ 0.01; ***, *P* ≤ 0.001. E, qRT-PCR of lymphotoxin and TNFα transcripts in sorted human (hu) B cells (*CD19*; *n* = 4), hu CLL B cells (*CD19-CD55*; *n* = 3), and in the B-CLL cell line MEC-1 (*n* = 2). Transcript expression was normalized to *Gapdh*. Error bars indicate mean ± SEM. F, human MEC-1 cells (1 × 10^7^) were i.v. transferred into NOD/SCID/γ-chain−/− mice. On day 3 up to day 25, mice were treated with 100 µg LTβR-Ig (*n* = 3; right) i.p. in 7-day intervals, or control mouse IgG1 (MOCP21; *n* = 4; left). Representative spleen sections were stained 28 days after transfer for CD19^+^ MEC-1 cells (red) and CD21^+^CD35^+^ FDCs (red). Scale bars, 50 µm.
adoptive transfer, \textit{Eμ-Tcl1} leukemia cells lodged within the splenic B-cell follicles in close proximity to FDCs. In sharp contrast, \textit{Cxr5}−/− leukemia cells accumulated in the MZ of the spleen. Bajenoff and colleagues (46) showed that T and B lymphocytes are guided by FRCs and enter the WP across MZDCs. Here, we observed that \textit{Eμ-Tcl1} leukemia cells directly crossed the MZ sinus and reached the B-cell follicle faster than follicular B cells. Hence, leukemic cells exhibited remarkable functional similarity to MZ B-2 lymphocytes, which also shuttle directly from the MZ to the B-cell follicle (26). Gene expression profiling revealed a higher similarity of \textit{Eμ-Tcl1} leukemia cells with B-1 B cells, as compared with MZ B cells. This result is consistent with the initial classification of these tumors (47), and would also fit with several properties of the human unmutated variant of B-CLL. Although physiologic differences between murine and human B-cell populations exist, prohibiting definitive conclusions (48), similarities are also appreciated that affect structural restriction of the BCRs, the polyreactivity toward autoantigens, expression of CD5, and the presentation as activated-antigen experienced B cells (3, 9, 49). B-1 cells can induce and associate with FDCs in mice; however, trafficking routes of these cells have not been thoroughly analyzed (50).

CXCL13–CXCR5 signaling is crucial for B-cell migration under steady-state conditions and enhances antigen encounter and BCR-triggered B-cell activation (51). A strong correlation has been proposed between antigen-stimulated BCR signaling and the clinical course of CLL (3). Involvement of a microbial-derived or autoantigen component in the heavy chain Ig repertoire selection has been suggested in many CLL cases, leading to the occurrence of stereotyped BCRs (1, 52). Alternatively, a BCR-mediated antigen-independent, cell-autonomous signaling mechanism might account for CLL signaling activity. However, this \textit{in vitro} model does not rule out involvement of \textit{in vivo} extrinsic antigens as additional enhancers (53).

How could \textit{Eμ-Tcl1} leukemia B cells receive proliferation stimuli \textit{in vivo}? Using two-photon microscopy, we found that \textit{Eμ-Tcl1} leukemia cells showed decreased displacement rates and increased interaction times with follicular FDCs compared with leukemia cells outside this area. This could result from their cognate nature and ability to encounter antigen-laden FDCs. The preferred tumor cell localization in the FDC-rich GC light zone may also be due to the paracrine provision of growth-promoting factors (34, 35). BCR engagement, as evidenced by activated BTK, and the receipt of growth factors could act differentially during tumor ontogeny and in a complementary manner. In this view, a strong antigen dependence exists in early stages, followed by competition for natural ligand availability, then acquisition of additional oncogenic lesions, and, finally, selection for mutants that can co-opt autonomous signaling from either the BCR or their downstream effectors (54).

The differentiation of FDCs is essential for SLO organogenesis (55) and final FDC maturation crucially requires lymphoid tissue-inducer (LTI) cells and B cells expressing LTB6 (56). Consistent with previous reports that B-2 and B-1 B cells can induce the formation of mature FDC networks (50, 57), a human leukemia cell line efficiently induced FDC networks in NOD/SCID/\(γc\)-chain−/− mice. This implies that B leukemia cells themselves provide the crucial factors for FDC differentiation \textit{in vivo}. The cross-talk between leukemic B cells and rudimentary stromal cells could be of relevance for a posttherapeutic minimal residual disease state. Irradiation of WT mice elicited an accumulation of leukemia B cells around radio-resistant FDCs and MRCs. This spatial proximity accelerated the growth rate of the tumor cells, most likely through unimpeded access to FDCs.

Notably, much of the cellular proliferation in human CLL arises in pseudofollicular proliferation centers in SLO, which are unique to CLL among all other B-cell malignancies, but they are observed in inflamed tissues of patients with systemic autoimmune disorders as well (1). Functional similarities between inflammation- and CLL-associated proliferation centers may include their capacity to initiate or maintain autoantigen stimulation, indicating that autoimmune diseases and CLL could share part of their pathogenic trait. The occurrence of FDCs in proliferation centers has been reported (58), thus supporting the view that leukemia B cell–FDC encounter is a major source of cellular proliferation.

We infer from our data that leukemia cell–associated LTB6 confers the required ligand such that FDC networks can be induced \textit{de novo}. In this paracrine network, further FDC stimulation with cell-bound LTB6 can induce the expression of CXCL13 and other proinflammatory cytokines (59). To break this feedback loop, we treated mice with an LTB6-Ig fusion protein and found that targeting the LTB6R signaling pathway profoundly retarded murine CLL growth. FDC loss and CXCL13 reduction indicated that inhibition of stroma–lymphoma cell cross-talk can translate into an ameliorated clinical course. Targeting the stromal environment in SLOs is an appealing treatment option for indolent lymphoma because these benign compartments are subject to less selective pressure for mutations and epigenetic changes (60).

We propose that our stroma induction model can mimic an early pathogenic condition in which, upon arrival of transformed clonal CLL cells in SLO, leukemia cells encounter a microenvironment that enhances their proliferation. Reciprocally, tumor cells impose stroma remodeling. Increased proliferative activity in proximity to FDC networks could enhance genetic vulnerability, resulting in mutation acquisitions that render tumor cells increasingly independent from antigenic triggering (1).

When applying an LTB6-decoy receptor, selective targeting of the stroma interface alone led to tumor growth retardation; this strategy is applicable to a minimal residual disease state in which tumor cells might be protected in LT-dependent niches. Furthermore, it may be possible to inhibit leukemia cell access to antigen-presenting cells, either through selective interference with CXCR5 activity as shown here, or by targeting the FDC function in growth factor supply. Both immunologic treatments are rational strategies to complement traditional cytotoxic therapies for the cure of leukemia and lymphoma.

**METHODS**

More detailed methods can be found in Supplementary Methods.
Cancer Discovery | December 2014 | Volume 4 | Issue 12 | pages 1456-1463

CXC5 and Lymphotoxic-Dependent Leukemia Growth

**Microarray Data**

The microarray data presented in this publication have been deposited in NCBI's Gene Expression Omnibus (GEO) and are accessible through GEO series accession number GSE60925.

**Chemotaxis Assay**

Assays were performed in 5-μm-pore Transwell plates (Corning) for 4 hours at 37°C, exactly as described previously (16). CCL21, CXCL12, and CXCL13 were used at a concentration of 100 nmol/L, 25 nmol/L, and 300 nmol/L, respectively (R&D Research Diagnostics).

**Patient CLL Blood Samples**

Peripheral blood samples from treatment-naive CLL patients were purified over a Ficoll gradient. Tumor cells (CD19+CD5+) were FACs-sorted and RNA was immediately extracted. The study was conducted according to the Declaration of Helsinki and in accordance with local ethical guidelines; written informed consent of all patients was obtained.

**Generation of Primary Eμ-Tcl1 Leukemia Cells for Transplantation**

Eμ-Tcl1 transgenic mice were monitored for signs of disease by quantification of the frequency of tumor cells in peripheral blood by flow cytometry (CD3+CD5+). Spleen-derived leukemia cell suspensions were prepared from diseased mice (>8 months old and tumor cell load >50% in the periphery) by tissue homogenization, depletion of red blood cells, and FACs sorting.

**Cell Lines**

Murine bone marrow stromal cells (M2-10B4; ATCC-CRL-1972) were obtained from the ATCC in July 2010. The cells were passaged two to three times over a period of 3 weeks and aliquots were frozen in liquid nitrogen. All experiments were performed with these aliquots. The human FDC line FDC/HK was obtained from Y.S. Choi (Ochler Clinic foundation, New Orleans, LA) in 2011 and cultured as described above. No further authentication was done for both cell lines.

**In Vivo Blockade of the LTβ-Receptor Signaling Pathway**

Blocking LTβR-Ig [100 μg; murine receptor fused to mouse Ab IgG1; Biogen Idec or generated as described previously (62)] or isotype control antibody (MOPC 21) were injected repeatedly s.i.p. into tumor challenged and Eμ-Tcl1 transgenic mice, respectively.

**Statistical Analysis**

Results are expressed as arithmetic means ± SEM if not otherwise indicated. Values of P ≤ 0.05 were considered statistically significant, as determined by the unpaired Mann–Whitney test, the two-tailed unpaired Student t test, or the Wilcoxon signed rank test where appropriate.

**Disclosure of Potential Conflicts of Interest**

No potential conflicts of interest were disclosed.

**Authors’ Contributions**


Writing, review, and/or revision of the manuscript: K. Heing, M. Grau, R.A. Niesner, A.E. Hauser, T. Hehljans, J. Westermann, B. Dörken, M. Lipp, G. Lenz, A. Rehm, U.E. Höpken

Administrative, technical, or material support (i.e., reporting or organizing data, constructing databases): A.E. Hauser, R. Brink, A. Rehm

Study supervision: B. Dörken, M. Lipp, A. Rehm, U.E. Höpken

Acknowledgments

The authors thank Carlo Croce (Columbus University, Columbus, OH) and Jeffrey L. Browning (Biogen Idec, Cambridge, MA) for providing essential reagents and Heike Schwede and Kerstin Krüger for excellent technical assistance.

**Grant Support**

This work was funded by grants from the Deutsche Krebshilfe (grant number 107749), German Research Foundation (DFG), and the Berliner Krebsgesellschaft to U.E. Höpken and A. Rehm; grants from the DFG, the Deutsche Krebshilfe, and the Else Kröner-Fresenius-Stiftung to G. Lenz; the DFG-funded project “JMI-a network for intravital microscopy” to R.A. Niesner, Z. Cseresnyes, and A.E. Hauser; and by a Doctoral Scholarship from the Philipps-Universität Marburg to M. Grau.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Received January 28, 2014; revised September 11, 2014; accepted September 12, 2014; published OnlineFirst September 24, 2014.

**REFERENCES**


CXCR5 and Lymphotoxin-Dependent Leukemia Growth


Published OnlineFirst September 24, 2014; DOI: 10.1158/2159-8290.CD-14-0096

Downloaded from cancerdiscovery.aacrjournals.org on July 2, 2017. © 2014 American Association for Cancer Research.
Access to Follicular Dendritic Cells Is a Pivotal Step in Murine Chronic Lymphocytic Leukemia B-cell Activation and Proliferation

Kristina Heinig, Marcel Gätjen, Michael Grau, et al.

Cancer Discovery 2014;4:1448-1465. Published OnlineFirst September 24, 2014.

Updated version Access the most recent version of this article at: doi:10.1158/2159-8290.CD-14-0096

Supplementary Material Access the most recent supplemental material at: http://cancerdiscovery.aacrjournals.org/content/suppl/2014/09/24/2159-8290.CD-14-0096.DC1

Cited articles This article cites 62 articles, 30 of which you can access for free at: http://cancerdiscovery.aacrjournals.org/content/4/12/1448.full#ref-list-1

Citing articles This article has been cited by 5 HighWire-hosted articles. Access the articles at: http://cancerdiscovery.aacrjournals.org/content/4/12/1448.full#related-urls

E-mail alerts Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.